• banner
  • banner

MAKE HIGH QUALITY MEDICINE FOR HUMAN BEING

OUR PRODUCTS

LATEST NEWS

Shijiazhuang No. 4 Pharmaceutical Co., Ltd. is again ranking top 50 in China Chemical Drug R&D Strength
Shijiazhuang No. 4 Pharmaceutical Co., Ltd. is again ranking top 50 in China Chemical Drug R&D Strength

Shijiazhuang No. 4 Pharmaceutical Co., Ltd. is again ranking top 50 in China Chemical Drug R&D Strength

2021-09-24 16:08
Shijiazhuang No. 4 Pharmaceutical Co., Ltd. is ranking top 50 in China Chemical Drug R&D Strength Once Again

On September 18, at the 2021 Conference on High Quality Development of Health Industry and the sixth Summit for China Pharmaceutical R&D Innovation (PDI) held in Chongqing, the list of 2021 Chinese Chemical pharmaceutical R&D Strength TOP100 was announced, and Shijiazhuang No. 4 Pharmaceutical Co., Ltd. ranked 44th, once again ranked among the top 50 chemical pharmaceutical R&D strength in China.  

 

R&d investment is one of the important indicators of innovation capacity. According to Frost&Sullivan data, R&D investment of innovative pharmaceutical enterprises has continued to grow in the past five years. From 2016 to 2020, the total R&D investment in China has increased from 11.9 billion US dollars to 27 billion US dollars, with a compound annual growth rate of 22.7%.  Twenty-four companies on the list spent more than 500 million yuan on R&D in 2020, while eight spent more than 1 billion yuan on R&D.  

 

With the policy implementation execute, the pharmaceutical industry market is facing a constant adjustment and differentiation, competitive situation from production as the core to research and development ability and drug innovation as the core, mainly on research and development of innovative enterprises will usher in unprecedented opportunities for development.  


API Dexmedetomidine Hydrochloride Manufactured by SSY Group was Approved
API Dexmedetomidine Hydrochloride Manufactured by SSY Group was Approved

API Dexmedetomidine Hydrochloride Manufactured by SSY Group was Approved

2021-09-24 11:22

API Dexmedetomidine Hydrochloride Manufactured by SSY Group was Approved 

Recently API Dexmedetomidine Hydrochloride developed and applied by Hebei Guolong Pharmaceutical Co., Ltd., SSY Group was approved by NMPA to be used for the FPF.

FPF Dexmedetomidine Hydrochloride Injection (2ml:0.2mg) applied by SSY Group also got the MA from NMPA and treated as consistency evaluation completion. 

Dexmedetomidine is a α2 adrenergic receptor agonists, it is maily used for sedation during tracheal intubation and mechanical ventilation in patients undergoing surgery under general anesthesia.

Terbutalin Sulphate Nebuliser Solution MA is approved
Terbutalin Sulphate Nebuliser Solution MA is approved

Terbutalin Sulphate Nebuliser Solution MA is approved

2021-06-28 13:57
April 12, Shijiazhuang No. 4 Pharmaceutical Co., Ltd. gained the manufacture and registration approval of Terbutalin Sulfate Nebuliser Solution 2ml: 5mg from NMPA, it is viewed as consistency evaluaiton has been completed.

Terbutalin Sulfate Nebuliser Solution is used for relief bronchospasm associate with bronchial asthma, chronic bronchitis, emphysema and other pulmonary diseases.

It can only be administered though an atomizer, dilution is not in need.

Products R&D Center

The comprehensive R&D center with total building area of

13000 ㎡ and its Support Animals Experiment Center of

2500 ㎡ are composed of Chinese and Western Medicines

Laboratory, Quality Laboratory, Open Research Center and

Intercourse Center, which connects

Full-controlled Water System

The full-controlled water system adopts advanced two-stage reverse osmosis membrane filtration technology and multi-

effect energy-saving distillation technoligy, realizes automatic on-line detection, record, control and automatic flow

regulation, automatically

Full-controlled and full-closed...

The full-controlled batching system adopts the international leading techniligical design of tatally-enclosure system and realizes automatic cleaning, batching, weighing, on-line

sterlization and autimatic detection. It can exactly control

the content and typical

OUR FACTORY

Shijiazhuang No.4 Pharmaceutical Co., Ltd. All rights reserved

冀ICP备05007979号-1 Powered by www.300.cn